Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data‐Linkage Study
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70233 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Allison Mo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Transfusion Research Unit, School of Public Health & Preventive Medicine, Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourn…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Blood Transfusion, Erythrocyte Transfusion, Platelet Transfusion. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian and New Zealand Society of Blood Transfusion, National Health and Medical Research Council, National Blood Authority.
Abstract (Originalsprache)
Background
Real‐world data on transfusion needs of patients with myelodysplastic syndromes (MDS), and the impacts of disease‐modifying therapies (DMTs) are sparse. In 2011, 5‐azacitidine became the first funded DMT for MDS and chronic myelomonocytic leukaemia (CMML) patients in Australia and national patient blood management (PBM) guidelines were published.
Aims
Describe red blood cell transfusion (RBC‐T) and platelet transfusion (PLT‐T) burden in MDS/CMML and any changes since 2011.
Method
Retrospective longitudinal cohort study of all MDS/CMML patients in the state of Victoria (population 6.5 million) from 2009 to 2022, linking hospital admissions dataset, cancer and death registries.
Results
7043 patients (5715 MDS; 1328 CMML), with median follow‐up 1.8 years (interquartile range [IQR]: 0.5–4.0 years), had 55 048 RBC‐T and 10 749 PLT‐T episodes. By 5 years post‐diagnosis, patients had on average 14 RBC‐T and 3 PLT‐T admissions, with transfusion burden affected by MDS subtype. PLT‐T were significantly higher post‐2011 versus pre‐2011 (0.8 more PLT‐T admissions by 2 years, p < 0.001), with no difference in RBC‐T admissions.
Conclusion
Since 2011, RBC‐T burden has remained stable, but PLT‐Ts have increased. Given the potential costs and limited PLT inventories, this impacts blood supply planning and highlights the need for research to optimise PLT‐T in MDS/CMML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Transfusion Research Unit, School of Public Health & Preventive Medicine, Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, Australia.
- Monash Haematology, Monash Health, Melbourne, Australia.
- Austin Pathology and Department of Haematology, Austin Health, Melbourne, Australia.
- Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, Australia.
- Department of Haematology, Alfred Health, Melbourne, Australia.
ORCID-Profile: Allison Mo, Erica M Wood, Jake Shortt, Zoe K McQuilten
Förderung
- Australian and New Zealand Society of Blood Transfusion
- National Health and Medical Research Council
- National Blood Authority
- Monash University
- Haematology Society of Australia and New Zealand
Zitieren
APA
Mo, A., Thao, L. T. P., Wellard, C., Wood, E. M., Shortt, J., & McQuilten, Z. K. (2026). Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data‐Linkage Study. European Journal of Haematology. https://doi.org/10.1111/ejh.70233
Vancouver
Mo A, Thao LTP, Wellard C, Wood EM, Shortt J, McQuilten ZK. Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data‐Linkage Study. European Journal of Haematology. 2026. doi:10.1111/ejh.70233
BibTeX
@article{Mo2026,
author = {Mo, Allison and Thao, Le Thi Phuong and Wellard, Cameron and Wood, Erica M and Shortt, Jake and McQuilten, Zoe K},
title = {Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data‐Linkage Study},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70233}
}
EUVIMED